Literature DB >> 15260419

High osteolysis and revision rate with the hydroxyapatite-coated ABG hip prostheses: 65 hips in 56 young patients followed for 5-9 years.

Jan Blacha1.   

Abstract

BACKGROUND: There are few reports on the outcome of uncemented HA-coated cups in young patients. PATIENTS: I evaluated the 7-year (5-9) results of HA-coated hip prosthesis (ABG, Stryker) in a consecutive series of 65 primary arthroplasties on 56 patients (mean age 44 years). 2 patients were lost to follow-up and 3 died.
RESULTS: The cumulative survival rate with revision for any reason as endpoint at 9 years was 98% (95% CI, 96-100) for the stem, 69% (61-77) for the acetabular metal backing, and 59% (50-67) for the polyethylene liner. 15 of 65 cups were revised on average 6 years after the primary operation and 3 more are planned. Revisions were done in 3 hips because of loosening and migration of the cup, and in 12 hips because of wear and progressive osteolysis around stable components. Only hips with migration had clinical symptoms. Visual inspection of polyethylene liners revealed wear of the articulation in all cases, loosening of the locking mechanism in 10 cases and nonarticular surface deformity in 7 hips. All original stems are in situ although femoral osteolysis was seen in 12 cases and 1 hip was reoperated because of periprosthetic traumatic fracture. Despite the high revision rate, the clinical improvement was good: the average pre- and postoperative Harris Hip Scores at the most recent follow-up were 41 and 90, respectively.
INTERPRETATION: While the results on the femoral side were good, the survival rates of the acetabular cups were poor and we stopped using ABG I hip prostheses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15260419     DOI: 10.1080/00016470410001204

Source DB:  PubMed          Journal:  Acta Orthop Scand        ISSN: 0001-6470


  12 in total

1.  Early polyethylene wear and osteolysis with ABG acetabular cups (7- to 12-year follow-up).

Authors:  Sachin Badhe; Peter Livesley
Journal:  Int Orthop       Date:  2005-11-08       Impact factor: 3.075

2.  Eleven-year results of the ABG I hip replacement.

Authors:  W Y Kim; B N Muddu
Journal:  Int Orthop       Date:  2006-03-07       Impact factor: 3.075

3.  Risk factors for accelerated polyethylene wear and osteolysis in ABG I total hip arthroplasty.

Authors:  Jiri Gallo; Vitezslav Havranek; Jana Zapletalova
Journal:  Int Orthop       Date:  2009-02-13       Impact factor: 3.075

4.  THA with the ABG I prosthesis at 15 years. Excellent survival with minimal osteolysis.

Authors:  P N Baker; I A McMurtry; G Chuter; A Port; J Anderson
Journal:  Clin Orthop Relat Res       Date:  2010-07       Impact factor: 4.176

5.  Letter to the editor: THA with the ABG I prosthesis at 15 years: excellent survival with minimal osteolysis.

Authors:  Jiri Gallo
Journal:  Clin Orthop Relat Res       Date:  2010-04       Impact factor: 4.176

6.  The Results of Long-term Follow-up of Total Hip Arthroplasty Using Hydroxyapatite-coated Cups.

Authors:  Chang-Dong Han; Keun-Young Shin; Hyun-Hee Lee; Kwan-Kyu Park; Ick-Hwan Yang; Woo-Suk Lee
Journal:  Hip Pelvis       Date:  2015-12-30

7.  Uncemented and cemented primary total hip arthroplasty in the Swedish Hip Arthroplasty Register.

Authors:  Nils P Hailer; Göran Garellick; Johan Kärrholm
Journal:  Acta Orthop       Date:  2010-02       Impact factor: 3.717

8.  Male gender, Charnley class C, and severity of bone defects predict the risk for aseptic loosening in the cup of ABG I hip arthroplasty.

Authors:  Jiri Gallo; Vitezslav Havranek; Jana Zapletalova; Jiri Lostak
Journal:  BMC Musculoskelet Disord       Date:  2010-10-19       Impact factor: 2.362

9.  Clinical and radiological results of hydroxyapatite-coated acetabular cups.

Authors:  J Blacha; J Gagała
Journal:  Int Orthop       Date:  2004-08-14       Impact factor: 3.075

10.  Inferior survival of hydroxyapatite versus titanium-coated cups at 15 years.

Authors:  Maiken Stilling; Ole Rahbek; Kjeld Søballe
Journal:  Clin Orthop Relat Res       Date:  2009-03-28       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.